Repligen Corp (RGEN) Q2 2026 Earnings Call Highlights: Strong Growth and Raised Guidance
Repligen (RGEN) reported Q2 2026 earnings call updates. CEO Olivier Loeillot said order trends strengthened into Q2 and supported raised full-year guidance for 10.5% to 13.5% organic growth (midpoint 12%). Protein revenue grew about 50% on portfolio strength, and equipment orders improved with a book-to-bill above 1, building backlog for 2027.
How this was made
The 30-second read
Why it matters
Raised organic growth guidance (10.5% to 13.5%, midpoint 12%) is supported by improved order trends and Protein portfolio strength, while conversion timing constraints and ATF rebound assumptions define the risk range.
Market read
Traders can update expectations for organic growth and the probability-weighted upside/downside drivers (Protein momentum vs ATF rebound, and equipment conversion timing).
What to watch
Filtration order conversion is constrained by customer facility preparedness, which can delay revenue timing even when orders are strong.
Background
The piece summarizes Q&A from Repligen’s Q2 2026 earnings call, focusing on order trends, backlog visibility, and raised organic growth guidance.
Ticker impact
Repligen raised full-year organic growth guidance to 10.5% to 13.5% and cited improved order trends and Protein strength.
Moderately positive bias for the next few sessions, with follow-through risk if ATF rebound or conversion timing disappoints.
The article provides specific raised guidance and qualitative drivers (book-to-bill above 1, Protein mid-teens growth, ATF rebound as upside), which are actionable for positioning but lacks fresh financial statement numbers or a new contract award.
Market effects
Signals improving demand visibility in bioprocessing equipment and consumables, potentially read-across to ATF and Protein-related workflows.
No specific regional demand or macro driver cited beyond general industry softness assumptions.
No explicit global geography breakdown, but emerging biotech and new modalities tailwinds suggest broader end-market support.
Counterpoint
The upside case depends on ATF continuing its rebound and on customer readiness for capital equipment, so near-term conversion could still lag.
Key entities
- companyRepligen Corp
Guidance raise driven by improved order trends, Protein growth, and backlog build for 2027.
